Clinical Trial

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-10; most recent amendment 2026-01-26.
Status change: Not Yet Recruiting → Recruiting 2025-01-03
Trial Details
NCT Number NCT06639256
Lead Sponsor Sichuan Huiyu Pharmaceutical Co., Ltd
Conditions Safety, Tolerability, Efficacy
Enrollment 258 participants
Start Date 2024-10-24
Primary Completion 2026-05 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-28